drugset / Trial / NCT04945733
A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the activity of amivantamab in gastric cancer (GC) and esophageal cancer (EC) participants (Phase 2a), and to characterize the preliminary antitumor activity of amivantamab in selected GC and EC population (Phase 2b).
Timeline
- Start
- 2021-08-30
- Primary completion
- 2023-07-03
- Completion
- 2023-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | 1050 mg | Intravenous |
| Subject | Amivantamab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Amivantamab | Monoclonal antibody | 1750 mg | Intravenous |
| Subject | Amivantamab | Monoclonal antibody | 2100 mg | Intravenous |